Bob spoke well except when it came to explaining how Alexicool...

First 94 Last

Share
Profile

Follow
DDuck

806 Posts.

42

25/09/18

09:53

Post #: 35817905
Share

Originally posted by Sceptical Prophet ↑

I'm actually pleasantly surprised by how well spoken Bob is, he addressed things succinctly and with conviction. Clearly believes in his own products. I expected him to be a bit nerdier.

Unfortunately, the narrative for the last year or so has been "we don't believe anything Alexium says anymore" so it's still a waiting game.

However, if you were to dare look at it with a clean slate, a lot of promising things said.

"Alexicool sales will be 50% higher in CY19 than any previous period" ... well most of the revenue ever made by AJX has been Alexicool, so does that mean 150% x highest previous period of revenue? I'm going to guess a period is a quarter. Anyone remember the highest quarter? Didn't we get to $24M revenue at one point? So say a quarter is $6M and 50% higher makes that $9M.

"FR will make up over 50% of revenue within the next 24 months without much increase in operating costs due to the toll manufacturing model" ... so if in 6-12 months we get $9M revenue from Alexicool then 24 months later we'll have at least an equal $9M from FR, then that makes a minimum of $18M revenue as a bear case.

At this point, still content to wait patiently. The narrative seems to have improved over the last 6-12 months.

Expand

Bob spoke well except when it came to explaining how Alexicool sales will be 50% higher than some other period which left many confused as to how to calculate the figure. It would simply have been better to have provided a number.

Last edited by DDuck: 25/09/18

AJX Price at posting: 13.0¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

TX3

Canadian fieldwork yields multiple pegmatites for Trinex

AUG

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

RNU

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

TLX

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

There are more pages in this discussion • 24 more messages in this thread...

First 94 Last

Add AJX (ASX) to my watchlist

(20min delay)
Last 1.1¢		Change 0.000(0.00%)		Mkt cap ! $17.18M

Open	High	Low	Value	Volume
1.1¢	1.1¢	1.1¢	$358	32.5K

Buyers (Bids)

No.	Vol.	Price($)
2	97500	1.1¢

Sellers (Offers)

Price($)	Vol.	No.
1.2¢	2591500	2

View Market Depth

No.	Vol.	Price($)
2	97500	0.011
6	4732035	0.010
3	511210	0.009
2	182600	0.008
1	200000	0.007

Price($)	Vol.	No.
0.012	2591500	2
0.013	1758914	3
0.014	363311	2
0.015	36316	2
0.017	15000	1

Last trade - 11.27am 11/07/2024 (20 minute delay)

AJX (ASX) Chart

Bob spoke well except when it came to explaining how Alexicool...

Canadian fieldwork yields multiple pegmatites for Trinex

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Bob spoke well except when it came to explaining how Alexicool...

Top Stories

Canadian fieldwork yields multiple pegmatites for Trinex

Augustus sees imperial share rise on high-grade Cu and gold results at Ti-Tree

Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News